Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. It offers medical care and supplemental benefit plans to individuals. The company also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, it provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; and military services, such as TRICARE T2017 East Region contract. Further, the company engages in the operation of pharmacy benefit manager business; operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. It sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Humana Inc.

The latest update is out from Humana AB ( ($SE:HUM) ). Humana AB has announced the acquisition of Familiehjelpgruppen AS, a respected provider of f...

Humana AB Expands Preventive Care Services with Acquisition of Familiehjelpgruppen AS

Analysts are intrested in these 5 stocks: ( ($MNDY) ), ( ($HUM) ), ( ($MP) ) and ( ($OKLO) ). Here is a breakdown of their recent ratings and the


Monday.com, Humana, MP, Oklo: Trending by Analysts

The latest announcement is out from Humana ( ($HUM) ). Humana Inc. announced that its senior management will meet with investors and analysts throu...

Humana Reaffirms Earnings Guidance for December 2025

Hua Medicine ( ($HK:2552) ) has shared an update. Hua Medicine announced the grant of 20 million share options to three executive directors and 71 ...

Hua Medicine Grants Share Options to Drive Growth and Commitment

In a report released today, Andrew Mok CFA from Barclays maintained a Hold rating on Humana, with a price target of $234.00. Mok CFA covers the Hea...

Barclays Remains a Hold on Humana (HUM)

Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Humacyte yesterday and set a price target of $11.00. The company’s shares closed yes...

Current Quarter	$-4.01	Next Quarter	$10.16
Current Year	$17.08	Next Year	$12.19
QoQ Growth	+353.4%	YoY Growth	-28.6%
3Y EPS CAGR	N/A	Target Price	$283.61
Consensus	Buy	Upside	+5.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HUM	$268.45	+0.74%	1.13M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HUM	$268.45	+0.7%	1.13M
3
4
5
6

HUM

HUM

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Humana Inc. Data in Excel

Get Humana Inc. Data in Excel